the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C

Shanghai Rona Therapeutics Co., Ltd.

Status and phase: Completed; Phase 1

Conditions: To Reduce the LDL-C Level in Hypercholesteremia Patients

Treatments: Drug: RN0191

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT06132360

RN0191-102

Details and patient eligibility

About

This is a randomized, placebo-controlled, single ascending-dose (SAD) study of administered SC to adult subjects with elevated LDL-C. Subjects who have signed an Ethics Committee (EC)-approved informed consent form (ICF) and have met all the protocol eligibility criteria during screening may be enrolled into the study.

Enrollment: 32 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Male and female subjects, aged 18 to 60 years, inclusive
2. Body mass index between 18 and 32 kg/m2, inclusive, with body weight > 45 kg for females and >50 kg for males
3. Serum LDL-C ≥100 mg/dL (2.6 mmol/L) at screening and Day -1
4. Fasting triglycerides < 400 mg/dL (<4.52 mmol/L) at screening and Day -1

Exclusion criteria

1. Known underlying disease or medical condition that may have a potential impact on general safety assessment, lipid metabolism, or glucose metabolism, or surgical condition (including, but not limited to, bariatric surgery) that, in the opinion of the investigator, may interfere with the interpretation of the results of the clinical study
2. Received any medication including, but not limited to, statins, ezetimibe, or lipid-altering nutrients within 30 days prior to screening, or PCSK9 antibody within 90 days prior to screening, or any LDL-C-lowering siRNA therapy within 12 months prior to screening
3. History of multiple drug allergies or allergic reactions to oligonucleotides or N-acetylglucosamine (GalNAc)
4. Subjects with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 1.5 times the upper limit of normal (ULN) at the time of screening (one repeat of the screening assay is permitted) with clinically significant ALT and/or AST > ULN and ≤ 1.5 times the ULN as determined by the investigator
5. Any medical condition that, in the opinion of the Investigator, makes the subject unsuitable for enrollment or may interfere with the subject's participation in or completion of the study. This includes, but is not limited to: history or presence of cardiovascular disease (including peripheral arterial and cerebrovascular disease); diabetes mellitus (except for diabetes mellitus of pregnancy in remission); cerebrovascular accidents; and abnormal thyroid function.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Single Blind

---

32 participants in 4 patient groups

cohort 1

Experimental group

Description:

or placebo

Treatment:

Drug: RN0191

Cohort 2

Experimental group

Description:

or placebo

Treatment:

Drug: RN0191

Cohort 3

Experimental group

Description:

or placebo

Treatment:

Drug: RN0191

Cohort 4

Experimental group

Description:

or placebo

Treatment:

Drug: RN0191